Lisa provides editorial coverage of all aspects of Japan’s prescription drug market for Scrip and Pink Sheet, including company, market, pricing and regulatory developments, as well as publishing podcast content regularly in the local Japanese language. Lisa brings close to a decade of experience working in either international teams or reporting, writing and editing, including in broadcast media through an internship as a TV reporter in Canada. Most recently, she covered the IT sector for ITmedia Enterprise in Japan. Lisa is bilingual in Japanese and English. She speaks basic French and Mandarin with keen interests in learning new languages. She holds an MA in Fine Art from Tokyo University of the Arts as well as a Master’s in Journalism from the University of King’s College in Halifax, Canada.
Latest from Lisa Takagi
US priority review for Japanese firm's first-in-class ADHD drug could result in approval of a new option this year.
While several companies await regulatory approval decisions on their cell therapies in Japan, BioCardia proceeds with discussions on an NDA filing and Innovacel readies an IPO.
Japan's main pharma industry association to assist government agency's early research and drug discovery projects by providing expertise.
The US giant is narrowing its focus on obesity and cancer.
Late 2025 saw a flurry of policy moves in Japan ahead of this April's regular drug reimbursement price revision, with pharma industry groups decrying a related medical fee increase. But other positive changes are set to be implemented.
Plus deals involving SciNeuro/Novartis, Prazer/J&J, Haisco/AirNexis, Daiichi Sankyo/Genesis, AbbVie/Zelgen, ASK Pharm/Adlai Nortye, Harbour BioMed/Yantai Lannacheng, Hansoh/Hengrui and more.